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ACEAging is associated with appearance of white matter hyperintensities (WMH) on MRI scans. Vascular risk and
inﬂammation, which increase with age, may contribute to white matter deterioration and proliferation of
WMH. We investigated whether circulating biomarkers and genetic variants associated with elevated vascu-
lar risk and inﬂammation are associated with WMH volume in healthy adults (144 volunteers, 44–77 years of
age). We examined association of WMH volume with age, sex, hypertension, circulating levels of total plasma
homocysteine (tHcy), cholesterol (low-density lipoprotein), and C-reactive protein (CRP), and four polymor-
phisms related to vascular risk and inﬂammation: Apolipoprotein ε (ApoE ε2,3,4), Angiotensin-Converting
Enzyme insertion/deletion (ACE I/D), methylenetetrahydrofolate reductase (MTHFR) C677T, C-reactive pro-
tein (CRP)-286CNANT, and interleukin-1β (IL-1β) C-511T. We found that larger WMH volume was associated
with advanced age, hypertension, and elevated levels of homocysteine and CRP but not with low-density li-
poprotein levels. Homozygotes for IL-1β-511T allele and carriers of CRP-286T allele that are associated with
increased inﬂammatory response had larger WMH than the other allelic combinations. Carriers of the APOE
ε2 allele had larger frontal WMH than ε3 homozygotes and ε4 carriers did. Thus, in healthy adults, who
are free of neurological and vascular disease, genetic variants that promote inﬂammation and elevated
levels of vascular risk biomarkers can contribute to brain abnormalities. This article is part of a Special
Issue entitled: Imaging Brain Aging and Neurodegenerative disease.in Aging andNeurodegenerative
rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The aging brain undergoes multiple structural and functional
changes [1–3]. One of the most prominent among them is deterioration
of the cerebral white matter [4] that is evident in breakdown of myelin
[5,6] anddisruption ofmicrostructural organization [7,8]. A common ex-
pression of white matter aging is leukoaraiosis [9], which is observed on
T2-weightedMRI scans as areas of extremely high signal intensity. These
bright objects (white matter hyperintensities, WMH) reﬂect multiple
physiologic and pathologic changes, including ischemic lesions, loss
and deformation of myelin sheath, damage to the walls of small vessels,
gliosis, micro-hemorrhages, and breaches of the cerebro-spinal ﬂuid
(CSF)–brain barrier [10–12]. Since the earliest days of clinical MRI, it
was clear that WMH burden is associated with advanced age [13,14]
and is increased by vascular risk factors, such as hypertension [13–17].
Nonetheless, after accounting for age and manifest vascular risk, much
WMH volume variance remains unexplained. A substantial share ofpopulation variability in WMH burden is heritable [18–20]. However,
to date, the search for speciﬁc genes responsible for proliferation of
WMH with age has born little fruit [21]. Nonetheless, because vascular
risk increasesWMHburden, a pool of known genetic variants that affect
lipid homeostasis, blood pressure regulation, and formation of athero-
sclerotic pathology may yield genetic modiﬁers of WMH burden.
Several such genetic variants have been studied in conjunctionwith
individual differences in WMH load. Investigations of Apolipoprotein E
(APOE) gene that controls cholesterol trafﬁcking in the blood vessels
and whose alleles, ε2, ε3, and ε4, are associated with progressively
higher blood levels of cholesterol [22] and increases risk for Alzheimer's
disease (AD) [23] produced mixed results [24–27]. Moreover, in some
studies, ε2 allele that is associated with reduced risk for AD and lower
cholesterol levels predicted an increase inWMH load [28], and increase
in microangiopathy-related damage [29]. Variants of genes associated
with control of blood pressure, such as ACE deletion [30,31] has been
linked to increased WMH burden [32–35] and lacunar strokes [36].
Studies of a variant of methylenetetrahydrofolate reductase gene
(MTHFR C677T) that is associated with increased plasma levels of ho-
mocysteine, a risk factor for vascular disease and AD [37–39,42],
revealed inconsistent support for its role in WMH severity [27,40,41].
Homocysteine promotes inﬂammatory response [43] that may
have a signiﬁcant impact on brain aging [44–46] by producing neural
Table 1
Descriptive statistics for sample demographics, white matter hyperintensities, and
levels of the blood markers.
N Minimum Maximum Mean SD CV
Age 144 44 77 58.89 9.09 0.15
Education 144 12 20 15.91 2.61 0.16
MMSE 144 26 30 28.78 1.09 0.04
Systolic BP (mm Hg) 144 97.67 156.67 123.85 12.55 0.10
Diastolic BP (mm Hg) 144 60.00 106.67 76.06 7.51 0.10
Cholesterol (mg/dl) 142 119.00 318.00 202.30 38.67 0.19
LDL (mg/dl) 142 43.00 214.00 121.64 33.82 0.28
HDL (mg/dl) 142 26.00 106.00 55.46 14.96 0.27
Folate (ng/l) 143 5.40 42.30 18.57 5.04 0.27
B12 (ng/l) 143 158.00 1,200 560.88 258.39 0.46
Homocysteine (μmol/l) 141 5.10 30.50 9.43 3.08 0.33
CRP (mg/l) 142 0.12 46.44 3.50 5.85 1.67
Frontal WMH (mm3) 144 152.00 27216.00 1667.06 2728.32 1.64
Parietal WMH (mm3) 144 8.00 5712.00 274.21 592.74 2.16
Temporal WMH (mm3) 144 54.00 11156.00 1079.61 1378.56 1.28
Occipital WMH (mm3) 144 376.00 9892.00 2511.69 1899.02 0.77
MMSE — Mini-Mental State Examination; SD — standard deviation; CV — coefﬁcient of
variation (SD/mean); BP — blood pressure; LDL — low-density lipoprotein; HDL —
high-density lipoprotein; WMH — white matter hyperintensities.
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factors associated with brain injury and elevated risk for neurodegen-
erative disease is interleukin-1β (IL-1β) [47–57]. The levels of IL-1β
are controlled by the eponymous gene, IL-1β, a functional variant of
which, IL-1β C-511T, is associated with increased proinﬂammatory
response [55]. The TT genotype of the IL-1β has been linked to an in-
creased risk of small vessel disease [56], seizures [57], and AD [58],
which makes this variant a plausible candidate for inﬂuencing
WMH proliferation. Although IL-1β C-511T polymorphisms has been
linked to ventriculomegaly in schizophrenia [59] and reduction of
brain volume in bipolar disorder [60], its impact on the brain struc-
ture in healthy adults is unknown. A genetic variant associated with
another pro-inﬂammatory cytokine, IL-6, has been linked to in-
creased WMH load in a recent study [61], but the IL-1β C-511T effect
was not examined in that study.
Another inﬂammatory blood marker is C-reactive protein (CRP).
CRP and the proinﬂammatory cytokines are activated in response to
injury almost simultaneously [62] and act in synergy to promote ath-
erosclerosis and plaque instability thus increasing probability of ad-
verse cerebrovascular events [63]. Elevated plasma levels of CRP
have been linked to WMH load ([64], but see [65]), cognitive decline,
and dementia [66,67]. However, two studies of typical older adults
found no associations between several CRP polymorphisms and
WMH burden [61,68]. A common tri-allelic variant of the CRP gene
(CRP-286CNANT) displays signiﬁcant variations in CRP levels from
the lowest in C homozygotes to the highest in persons who do not
carry the C allele [69].
In this study, we examined the effect of inﬂammation-associated
polymorphisms IL-1β C-511T and CRP-286CNANT on WMH volume
in healthy adults of a broad age range. We compared the effect of
these proinﬂammatory genetic variants with previously explored ge-
netic factors linked to vascular risk: ACE insertion deletion, MTHFR
C677T, and ApoE ε2, e3, and e4 variants. Furthermore, we examined
the interactive effects between a known vascular risk factor, hyper-
tension, and these genetic variants on WMH volume.
2. Method
2.1. Participants
The sample was part of a larger ongoing study of neural correlates
of cognitive aging. Participants were residents of a major Midwestern
metropolitan area in the United States and all lived independently.
The exclusionary criteria were as follows: a history of cardiovascular
(except treated essential hypertension), neurological, or psychiatric
illness, diabetes, head trauma with a loss of consciousness for more
than 5 min, thyroid problems, treatment for drug and alcohol prob-
lems, or a habit of taking three or more alcoholic drinks per day,
and use of anti-seizure medication, anxiolytics, or antidepressants.
The participants scored below 16 on the Center for Epidemiologic
Studies Depression Scale (CES-D) [70] and above 25 on the Mini Men-
tal State Examination (MMSE) [71]. All participants were strongly
right-handed as indicated by the Edinburgh Handedness Question-
naire (75% and above) [72]; left-handers were excluded from this
study. Participants were classiﬁed as hypertensive if they had a diag-
nosis of hypertension, were taking antihypertensive medications, or if
their blood pressure averaged over three to four testing sessions
exceeded 140 mm Hg (systolic) or 90 mm Hg (diastolic).
One-hundred and forty four participants (98 women and 46 men)
were included in the study. Approximately 27% of participants were
African-Americans. The sample included 49 persons classiﬁed as hy-
pertensive according to the above listed criteria. Participants who
had diagnosis of hypertension were taking the followingmedications:
ACE inhibitors— 12, diuretics— 11, angiotensin II blockers— 10, beta-
blockers — 9, Ca channel blockers — 6, and alpha-1 blockers — 1. Ten
participants were taking two antihypertensive medications. Thirteenparticipants were taking statins for reduction of cholesterol, but
there was no difference in proportion of people on statins between
normotensive and hypertensive participants: 8% vs. 10%, χ2=.13,
p=.72. Eight women were on hormone-replacement therapy (HRT)
and additional 24 women used HRT in the past. Among normotensive
women, 35% were current or previous HRT users, whereas among hy-
pertensive women — 43%, a nonsigniﬁcant difference: χ2=.57,
p=.45.
The sample consisted of participants with a high educational at-
tainment that corresponded on average to almost four years of col-
lege. Men and women did not differ in age (t=−0.97, p=.33),
education (t=−0.01, p=.99), and MMSE scores (t=1.44, p=.15).
The demographic characteristics of the sample and descriptive statis-
tics for blood markers are presented in Table 1.
2.2. Procedure
2.2.1. MRI acquisition
Images were acquired on a 4-Tesla MRI system (Bruker Biospin,
Ettlingen, Germany) with an 8-channel RF coil. A set of 50 contiguous
axial slices of ﬂuid-attenuated inversion recovery (FLAIR) images was
acquired with following parameters: TR=8440ms, TE=112 ms,
TI=2200 ms, FA=150°, FOV=256×256 mm2, in plane resolution=
1×1mm2, slice thickness=2mm, matrix size=256×256. All MR
scans were screened for space-occupying lesions and an experienced
neuroradiologist reviewed all suspicious cases.
2.2.2. Quantiﬁcation of white matter hyperintensities
White matter hyperintensities were identiﬁed on axial slices of
the FLAIR sequence. Hyperintense regions were deﬁned as circum-
scribed areas of increased signal intensity within the white matter.
Because of the difﬁculty in differentiating WMH from emerging
blood vessels and sulci in the superior convexity, the last slice on
which WMH were traced was located three slices below the vertex
[73]. All identiﬁable periventricular and deep WMH were included.
WMH were measured on the frontal (FWMH), parietal (PWMH),
temporal (TWMH), and occipital (OWMH) lobes. The volume of
WMH for each region and each type were calculated as a sum of the
areas of hyperintensities multiplied by the slice thickness. A total
WMH volume was obtained by summing the volumes of hyperinten-
sities from all of the ROIs.
Intraclass correlation (ICC) [74] was used to assess intra-rater re-
liability of the WMH volumes from the data collected by one rater
who traced 10 randomly chosen brains on two separate occasions,
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all types of WMH were or exceeded 0.90. The rater, who was blind to
the participants' age, sex, and hypertension status, performed all
WMH measurements. Regional demarcation was based on published
rule used by Gunning-Dixon and Raz [73].
2.2.2.1. Frontal lobe. The frontal region covered the region anterior to
the lateral sulcus on ventral slices. The central sulcus served as the
caudal boundary on dorsal slices. The intra-rater reliability of frontal
WMH was ICC=.95.
2.2.2.2. Temporal lobe. On ventral slices, the lateral ﬁssure served as the
anterior boundary of the temporal region, and the temporal–occipital
incisure was the posterior boundary. The parieto-occipital sulcus
appeared medially on superior slices, and a horizontal line was
drawn from the parieto-occipital sulcus to the lateral surface of the cor-
tex to separate the occipital and temporal regions. The temporal WMH
was traced until the slice on which the superior temporal gyrus was no
longer present (usually the slice inferior to the last slice of the corpus
callosum). The intra-rater reliability of temporal WMH was ICC=.98.
2.2.2.3. Parietal lobe. The parietal region emerged on the most inferior
slice where the central sulcus could ﬁrst be identiﬁed. On ventral
slices, the central sulcus was the anterior boundary, and the lateral
ﬁssure served as the posterior boundary separating the parietal
from temporal regions. On dorsal slices (beginning with the last
slice on which the corpus callosum was observed), all white matter
posterior to the central sulcus was included in the parietal region.
The intra-rater reliability of WMH in this region was ICC=.95.
2.2.2.4. Occipital lobe. The occipital region covered the area posterior
to the temporal–occipital ﬁssure (laterally) and the parieto-occipital
sulcus (medially). The intra-rater reliability of WMH in this region
was ICC=.95.
2.2.3. Blood biomarker measurements
Following an overnight fast of 12 h, participants reported to the
clinic between 9 and 10 am, and donated approximately 20 cm3 of
whole blood for the analysis of plasma lipids, CRP, Hcy, vitamin B12,
and folate. Samples for Hcy assays were placed in EDTA tubes on
ice, and centrifuged to separate plasma within 30 min after venipunc-
ture. The remaining samples were placed in serum separator tubes.
All samples were processed in-house within four hours of venipunc-
ture. CRP concentration was determined by immunoturbidimetry;
total plasma homocysteine tHcy was assayed by ﬂuorescence polari-
zation immunoassay, and serum vitamin B12 and folate — by chemi-
luminescence. Due to laboratory errors, two lab samples were lost for
tHcy and one for CRP, thus leaving at least 142 available for blood bio-
markers analyses.
2.2.4. Blood pressure measures
Blood pressure was measured on three or four separate days at the
start of each cognitive test session by a mercury sphygmomanometer
(BMS 12-S25) with a standard blood pressure cuff (Omron Profes-
sional) on the left arm with participants seated, and their forearm po-
sitioned on the table. Trained laboratory technicians conducted the
measurements. The systolic and diastolic means across the measure-
ment occasions were computed for each individual.
2.2.5. Genotyping
DNA was isolated from buccal samples obtained in mouthwash.
Isolation was performed using a Gentra Autopure LS with the stan-
dard buccal cell protocol. For genotyping quality control, 37% direct
repeats and DNA sequencing for veriﬁcation were performed. Both
control DNA and no-template controls were used. Success rate of gen-
otyping at the ﬁrst run was 96.25%. However, after direct repeatquality control runs with at least four successful identiﬁcations re-
quired for a call, only one sample showed an allele dropout
(99.38%). After direct repeat analyses were performed seven times,
the sample was genotyped with an estimated error of 0.33%. Thus,
the ﬁnal genotyping success rate for this study was 100%.
2.2.5.1. IL-1β C-511T (rs16944). Polymorphism for IL-1β C-511T was
interrogated with the 5′-nuclease assay using a Taqman SNP Geno-
typing assay (Applied Biosystems, Foster City, CA, USA). The allelic
distribution of the IL-1β C-511T polymorphism ﬁt the Hardy–Weinberg
(HW) equilibrium (χ2=2.14, p=.14), with 38% of participants being C
homozygotes (n=55), 42% C/T heterozygotes (n=61), whereas 28 par-
ticipants had the homozygous TT genotype (19%). Variant allele fre-
quency was 0.59. For analyses, two groups were formed: IL-1β-511T
homozygotes (n=28) and C allele carriers. The two groups did not dif-
fer in age (t=.65, p=.52), education level (t=.60, p=.54), and MMSE
(t=.46, p=.65).
2.2.5.2. MTHFR C677T (rs1801133). The MTHFR C677T polymorphism
was interrogated with the 5′-nuclease assay using a TaqMan SNP
Genotyping Assay (Applied Biosystems, Foster City, CA, USA). The as-
says were run using an Applied Biosystems 7900. Genotyping
revealed that 54 (37%) participants were heterozygous (CT), 11
(8%) were homozygous for the T allele (TT) and 79 (55%) were homo-
zygous for the C allele (CC). The distribution of the alleles conformed
to the HW equilibrium: χ2=.17, pb0.67. Variant allele frequency
was .26. Because of dearth of TT homozygotes, we conducted analyses
on comparison between carriers of the T allele and CC homozygotes.
The carriers of the T allele differ from MTHFR C677 homozygotes in
age (t=.459, p=.52), education (t=1.21, p=.23), or MMSE
(t=.83, p=.41).
2.2.5.3. CRP-286CNTNA (rs3091244). The CRP polymorphism was PCR
ampliﬁed using forward 5′-AGGTGTCAGAGCTTCGGGAAGAG-3′ and
reverse primers 5′-GCTCTGGGAGGAGCATGTTTGTTT-3′ in a 25 μl re-
action containing 2.5 mmol/l MgCl2, 0.5 μmol/l of the primers,
1.25 U AmpliTaq Gold polymerase, and 200 μmol/l dNTPs. The mix-
ture was denatured at 95 °C for 5 min and ampliﬁcation achieved by
15 cycles of 94 °C for 30 s, 66 °C for 30 s, and 72 °C for 1 min, followed
by a ﬁnal extension at 72 °C for 10 min. The amplicons were puriﬁed
using Sephadex and the puriﬁed products were analyzed on an ABI
PRISM 3700 DNA Analyzer using a 50 cm capillary array. The distribu-
tion of CNA and CNT alleles met HW equilibrium requirements:
χ2=.34, p=.56; and χ2=.002, p=.97, respectively. There was
only one TT homozygote, and for the analyses, we combined all T al-
lele carriers (N=23) and compared them to persons lacking that
allele.
2.2.5.4. ACE insertion/deletion. Allelic discrimination of the ACE inser-
tion/deletion were accomplished using a 5′-nuclease assay adapted
from a quantitative PCR method as described by Lo et al., 2000 (Lo,
YMD, Lau TK, Chan LYS, Leung TN, and Chang AMZ. Quantitative analy-
sis of the bi-directional fetomaternal transfer of nucleated cells and
plasma DNA. Clinical Chemistry 2000; 46(9): 1301–1309.). DNA will
be ampliﬁed using either ACE-1721F (insertion) or ACE-1428F (dele-
tion) and ACE-1826R. Ampliﬁcation were detected with the TaqMan
probe 1745T. Beta-globin were utilized as a housekeeping gene for
quantitation. Controls have been established by sequencing for I/I, I/D,
and D/D. No template controls were used. The insertion/deletion het-
erozygotes constituted approximately half the sample (45%, 65 individ-
uals), and 26% of the participants (N=37) were I/I homozygotes, and
29% (N=42) carried two D alleles. The frequency of the variant (D) al-
lelewas .52. The distribution of ace I/D alleles conformed toHWequilib-
rium: χ2=1.33, p=0.25. DD homozygotes did not differ from ACE I
carriers in age (t=.49, p=.63), education (t=1.31, p=.19), or
MMSE (t=.06, p=.95).
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were preampliﬁed with forward 5′-CAATGCTACCGAGTTTTCTTCC-3′ and
reverse primers 5′-TTCAGATTCTTCACAGATGCGTA-3′ in a 25 μl reaction
containing 2.5 mmol/l MgCl2, 0.5 μmol/l of the primers, 1.25 U AmpliTaq
Gold polymerase, and 200 μmol/l dTTPs. The mixture was denatured at
95 °C for 10 min and ampliﬁcation achieved by 15 cycles of 94 °C for
30 s, 58 °C for 30 s, and 72 °C for 1 min, followed by a ﬁnal extension at
72 °C for 10min. One μl of this reaction was subsequently used for
rs429358 and rs7412 5′-nuclease assays under standard conditions. The
primers and probes for the rs7412 assay were 5′-TCCGCGATGCCGAT-
GAC-3′, 5′-CCCCGGCCTGGTACAC-3′, VIC-CAGGCGCTTCTGC-NFQ and
FAM-CAGGCACTTCGC-NFQ. The primers and probes for the rs429358
assay were 5′-GCGGGCACGGCTGT-3′, 5′-GCTTGCGCAGGTGGGA-3′, VIC-
CATGGAGGACGTGTGC-NFQ and FAM-ATGGAGGACGTGCGC-NFQ. There
were 19 ε2 carriers (three homozygotes), 93 ε3 homozygotes and 32 ε4
carriers (two of them homozygotes); there were no ε2/ε4 heterozygotes.
For ε4 vs. ε3, HW equilibrium was maintained: χ2=0.06, p=.81, and
variant allele frequencywas 0.14. However, for ε2 vs. ε3 alleles, the distri-
bution departed from HW equilibrium: χ2=4.19, p=.04, variant allele
frequency 0.10. The three allelic groupings (ε2 carriers, ε3 homozygotes,
and ε4 carriers) formed a three-level ApoE variable for the analyses.
There were no signiﬁcant differences among the ApoE allelic groupings
in age (F=1.82, p=.17), education (F=1.27, p=.29), or MMSE (Fb1).
2.2.6. Statistical analyses
The data were analyzed within a General Linear Model (GLM)
framework, with log-transformed WMH volume as the dependent
variable, lobes (frontal, parietal, temporal, and occipital) as a four-
level repeated measures factors, sex and hypertension diagnostic
group (normotensive vs. hypertensive) as categorical predictors,
and age (centered at the sample mean) as a continuous predictor.
To test the effects of each of the polymorphisms, we added each as
a categorical predictor into the basic model described above. Due to
a small number of participants with speciﬁc combinations of alleles,
we could not test for epistatic effects of the genes within the same
model. All models contained ﬁrst-order interactions among all pre-
dictors. We used Hyuhn–Feldt correction to adjust the probability
levels of all interactions that involved repeated measures for violation
of sphericity assumption.
In each analysis, a full model that included all second-order inter-
actions was tested ﬁrst. All interactions that did not reach statistical
signiﬁcance (pN0.15) were removed from the model and the data
were ﬁtted to a reduced model. The GLM analyses were followed by
univariate analyses of simple effects, and testing the differences
among the levels of the categorical variables with Fisher's Least Sig-
niﬁcant Difference (LSD) test, or correlation coefﬁcients with Steiger's
Z* statistic that takes into account dependence between the com-
pared correlations [75].
3. Results
The distributions of all biomarkers were skewed and application
of a ln(x) transformation normalized most of them, except for folate
and vitamin B12. Log-transformed values were used in all analyses.
3.1. Blood marker levels
About 50% of all participants had elevated cholesterol, but of 13 sta-
tins users, only one had cholesterol level in excess of 200 mg/dl (border-
line high). Total cholesterol levels were reliably lower in persons who
took statins: F(1,142)=18.44, p=.0003, after adjustment for age and
sex. The difference inmean valueswas between 202.35 mg/dl for partic-
ipants who did not take statins and 160.77 mg/dl for those who did.
Most participants had normal LDL values, but 28% had borderline high
(over 130 mg/dl) and 13% had elevated LDL (above 160mg/dl).Twenty six participants (13 women) met criteria for hyperhomo-
cysteinemia (HcyN12 μmol/l), and they had lower though normal fo-
late levels than the participants with normal Hcy levels: t(139) 4.01,
p=.0001. None of the participants was deﬁcient in folate and 45%
of them exceeded the recommended range, with the sample range
between 5 and 42 ng/l. The hyperhomocysteinemia group did not dif-
fer from the rest of the sample on B12 levels: t(139)=0.99, p=.32.
For vitamin B12, the range was 158–1200 ng/l, with 38% of the partic-
ipants outside of the normative 200–600 ng/l range; 37% above the
normal value and one person below: 158 ng/l. For 6% of the partici-
pants, CRP levels exceeded the norm (10 mg/l) and were indicative
of an ongoing inﬂammatory process.
3.2. Effect of genetic variants on vascular risk factors
Only one of the examined polymorphisms, ACE I/D, was signiﬁcantly
associated with diagnosis of hypertension. Among normotensive partic-
ipants, only 23% were ACE D homozygotes, whereas among their hyper-
tensive counterparts, theACEDDgenotypewas almost twice as frequent:
42%, χ2=4.88, p=.027. Notably, the distribution of persons taking any
medication that directly targeted renin–angiotensin system was unre-
lated to the ACE genotype: χ2=.002, p=.98. The share of homozygotes
for IL-1β-511T allele was 16% among normotensive and 27% among hy-
pertensive participants, χ2=2.38, p=.12. No difference in frequency of
MTHFR 677T allele was noted: 54% vs. 57%, for normotensive and hyper-
tensive participants, respectively, χ2=0.17, p=.69. There were 23% of
ApoE ε4 carriers among normotensive vs. 30% among hypertensive par-
ticipants, χ2=0.60, p=0.44. Proportions of ApoE ε2 carriers also did
not differ between the groups: 11% among normotensives vs. 18%
among hypertensive participants, χ2=1.74, p=0.19.
There was a signiﬁcant difference in LDL levels according to ApoE ε
variants: F(1,135)=4.62, p=.01. Carriers of ε4 allele had higher LDL
levels than ε2 carriers did and marginally higher than those of ε3 ho-
mozygotes; there was no difference in LDL levels between the ε3 and
ε4 groups. Although the trend for total cholesterol levels was in the
same direction, no effect of ApoE ε variant on the level was observed:
F(1,135)=2.00, p=.13.
We examined the effects of age, sex, hypertension andMTHFR C677T
on themeasured levels of threemetabolically linked biomarkers: Hcy, fo-
late, and vitamin B12, as repeatedmeasureswithin the samemodel. There
was a signiﬁcant main effect of age: F(1,135)=9.44, p=.003. However,
the effects were qualiﬁed by a signiﬁcant age×sex×biomarker interac-
tion: F(2,270)=3.55, p=.03. Decomposition of the interaction showed
that among women, the levels of two biomarkers Hcy (r=.41,
p=.00003) and B12 (r=.31, p=.002) correlated positively with age,
with no age differences noted for the folate levels (r=.07, p=.50). For
men, no signiﬁcant age differences were noted in any of the biomarkers
(r=.17, −.11, .16, all pN .25). Notably, no effects involving MTHFR
C677T were signiﬁcant (all Fb1).
Carriers of T allele of the CRP-286CNANT polymorphism had reli-
ably higher plasma levels of CRP: 2.76 mg/l vs. 1.47 mg/l than those
who did not carry that allele; F(1,138)=5.45, p=.02. There were
neither age nor sex differences in CRP levels: F(1,138)=1.13,
p=.29, and F(1,138)=1.34. p=.19, respectively. Among persons
with high CRP levels indicative of inﬂammation, 44% were carriers
of T allele, whereas among participants with normal CRP levels, only
13% carried the allele, χ2=6.15, p=.01.
3.3. Effect of age, sex, hypertension, and genetic variants on WMH volume
3.3.1. Age, sex, and hypertension
In the ﬁrst model (referred hereon as the basic model), we exam-
ined age-, sex-, and hypertension-related differences in WMH vol-
ume, by lobe, without taking into account genetic variation. As none
of the interactions among the between-subject factors was signiﬁcant
(all pN .15), they were removed from the model. The analysis of the
Fig. 1. Volume of the white matter hyperintense regions in frontal, parietal, temporal
and occipital lobes in carriers of the ancestral C allele and TT homozygotes of the single
nucleotide polymorphism IL-1β C-511T. Bars are standard errors; stars indicate signif-
icant differences between the lobes.
Fig. 2. Volume of frontal, parietal, temporal and occipital white matter hyperintensities
grouped according to hypertension diagnosis and presence of CRP-286T allele that is
associated with highest homocysteine levels. Bars are standard errors; stars indicate
signiﬁcant differences between the lobes.
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pb .000001), but neither sex differences (Fb1), nor a main effect of
hypertension (F(1,140)=1.68, p=.20, ns). However, there were
three signiﬁcant interactions with Lobe, indicating that each of
those factors had a differential effect on WMH, depending on the
location.
Lobe×Age interaction (F(3,420)=6.67, p=.0005) was due to the
fact that the association with age was the weakest for occipital WMH
volumes: r=.26, p=.002, followed by the parietal (r=.42,
pb .00001), frontal (r=.47, pb .0001), and temporal (r=.58,
pb .0001) lobes. Steiger's test for differences in correlated correlations
showed that the temporal lobe WMH had the closest association with
age: Z*=4.20, pb .0001 for temporal vs. occipital, Z*=2.08, p=.037
for temporal vs. frontal and Z*=2.80, p=.005 for temporal vs. parie-
tal comparisons. Among all lobar WMH, the occipital showed the
weakest association with age: Z*=2.28, p=.02 for comparison
with the frontal, and Z*=1.89, p=.056 for comparison with the pa-
rietal. A signiﬁcant Lobe×Hypertension interaction (F(3,440)=4.48,
p=.007) reﬂected a hypertension-related increase in WMH volume
restricted to the frontal lobe: F(1,140)=4.61, p=.03, with a trend
in the temporal lobe (F(1,140)=3.16, p=.077). The WMH volumes,
adjusted for age and sex, were 1205.92 mm3 for hypertensive partic-
ipants vs. 906.87 mm3 for their normotensive counterparts.
There were no differences in the parietal (F(1,140)=1.81,
p=.18), or occipital (F(1,140)=2.08, p=.15) lobes. A signiﬁcant
Lobe×Sex interaction (F(3,440)=4.09, p=.01 reﬂected the discrep-
ancy in the direction of sex differences trends among the lobes, with
some favoring men, and other—women. However, none of the trends
was signiﬁcant, with the closest to the conventional 0.05 level being a
trend toward a greater WMH load in the occipital lobe for men:
F(1,140)=3.12, p=.08).
The next step was to examine the effects of target polymorphisms
on WMH volume, while taking into account the inﬂuence of age, sex,
and hypertension. The effects were tested one at time, by adding the
respective allelic grouping to the model described above.
3.3.2. IL-1β-511T homozygotes vs. C carriers
The main effect of IL-1βT was marginally signiﬁcant: F(1,139)=
3.78, p=.05. It was modiﬁed by Lobe×IL-1β interaction: F(3,417)=
3.69, p=.02. The effect, illustrated in Fig. 1, was limited to the frontal
and parietal lobes, in which T homozygotes'WMH volumes were larger
than those of the C carriers: F(1,139)=5.07 and 7.04, p=.03 and .01,
respectively. After removal of one outlier (71 year old hypertensive
woman; Studentized residual=3.64), the observed effects became
stronger: F(1,138)=4.56, p=.034 for the main effect, and F(3,212)=
4.08, p=.01 for IL-1B×Lobe interaction. The main effect of age and
lobe×age, lobe×hypertension, and lobe×sex interactions observed in
the ﬁrst model did not change with addition of the Il-1β. All the basic
model effects described above (age and lobe×age, lobe×hypertension,
and lobe×sex interactions) remained signiﬁcant.
3.3.3. CRP-286CNANT: T carriers vs. the rest
The main effect of CRP T allele was not signiﬁcant Fb1. However,
two interactions involving the CRP factor were: CRP×Hypertension
(F(1,138)=12.23, p=.004) and CRP × Hypertension × Lobe
(F(3,414)=2.93, p=.04). Decomposition of the triple interaction
revealed that CRP×Hypertension effect on WMH volume was signif-
icant for the frontal, temporal and parietal lobes: F(1,138)=13.56,
7.46, and 4.85, p=.0003, .01, and .03, respectively. No differences
were observed in the occipital lobes. For frontal and temporal lobes,
WMH volumes of persons who had hypertension and CRP T allele
were signiﬁcantly larger than those of participants who were normo-
tensive, or non-carriers of T, or neither. Fisher Least-Signiﬁcant Differ-
ence Test probabilities for pair-wise comparisons ranged from .0007
to .003. For parietal WMH, the differences were smaller and the Fisher'sLSD probabilities ranged from .02 to .06. The results are illustrated in
Fig. 2. All effects observed in the basic model remained signiﬁcant.3.3.4. APOE ε variants: Comparison of ε2 carriers vs. ε3 homozygotes vs.
ε4 carriers
There was no main effect of APOE ε variant: F(2,138)=1.11,
p=.33. However, there was a signiﬁcant Lobe×APOE interaction:
F(6,414)=3.28, p=.006. Decomposition of this interaction revealed
that APOE ε2 allele was associated with the largest frontal WMH, al-
though the univariate test fell short of signiﬁcance: F(2,138)=2.72,
p=.07. No effect of APOE allele on WMH was observed in other
lobes. In the frontal white matter, the WMH volume in ε2 carriers
exceeded that of the ε3 homozygotes (Fisher's p=.03) and ε4 car-
riers (Fisher's p=.03), with the latter two groups showing no differ-
ence (Fisher's p=.68). The main effect of age and lobe×age,
lobe×hypertension, and lobe×sex interactions observed in the ﬁrst
model did not change with addition of the APOE as a factor. All the
basic model effects remained signiﬁcant.
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DD homozygotes vs. I carriers
There was no signiﬁcant main effect of MTHFR 677T allele or ACE
DD genotype, nor was there any Lobe×polymorphism interaction:
all F'sb1. All the basic model effects remained signiﬁcant.3.4. Effects of blood biomarkers on WMH volume
We also examined if the actual, measured levels of biomarkers —
homocysteine, CRP, and LDL were associated with WMH volume.
The general linear models analyses with each of the biomarkers'
levels entered (after centering at the sample mean) in separate
models, revealed no effect of tHCy, LDL or CRP (all Fb1). In contrast,
tHcy in interaction with age was associated with WMH volume:
F(1,134)=4.20, p=.04. The strength and shape of that association
varied across the cerebral lobes, as indicated by Lobe×Age×Hcy in-
teraction: F(3,402)=6.14, p=.0001. These associations are illustrat-
ed in Fig. 3 that shows on tri-variate surface plots that in frontal,
parietal, and temporal lobes WMH volume was the greatest for
older participants with high tHcy levels, whereas for the occipital
WMH, the greatest volume was observed for middle-aged persons
with elevated tHcy.Fig. 3. Surface response plots of the tri-variate associations among age, plasma total homoc
formed, cm3) in four cerebral lobes (the response variable, color coded). Color temperature4. Discussion
The novel ﬁnding in this study is that in healthy adults, genetic
tendencies for increased inﬂammation are associated with increased
volume of white matter hyperintensities. In the case of the CRP-
286CNANT polymorphism, genetic and physiological risks combined
to produce greater WMH burden than was associated with either of
them alone. Notably, the negative impact of the risk-associated alleles
was greater and more consistent in the frontal and temporal lobes,
with parietal WMH showing weaker associations and occipital
WMH not showing any impact at all.
In contrast, two genetic variants linked to increase in vascular risk,
ACE I/D andMTHFR C677T, showed no effect onWMH burden. Among
the alleles of the third vascular-risk variant, APOE ε, only ε2 was asso-
ciated with increase in WMH and only in the frontal lobes. As
expected from the extant literature, we observed age-related and
hypertension-related increases of about 30% in WMH volume
[13,14], with both being prominent in the frontal lobe [17]. In con-
trast to some of the previous reports [76], we observed no clear pat-
tern of sex differences in distribution and volume of WMH.
Differential vulnerability of the frontal lobes to aging [17,77], and
to vascular risk [17,78–80] has been well documented. Although in
some studies, parietal cortices exhibit rapid age-related shrinkage asysteine (log-transformed, μmol/l), and white matter hyperintensity volume (log-trans-
scale corresponds to the WMH volume: hotter colors reﬂect larger volumes.
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The frontal lobes stand out as the regions, in which unlike in the
other parts of the brain, almost all middle-aged and older healthy
adults have at least some WMH [17,79,82] and in which the longitu-
dinal rate of WMH expansion is faster than in other lobes [83]. Only
presence of WMH in the frontal lobe correlates with postmortem
AD pathology [84], and vascular risk (hypertension) exacerbates
WMH burden in the frontal lobes [17,79,80,82]. In acute ischemic
stroke, the frontal regions withstand the worst of the damage [85].
Of course, the difference between the frontal lobe and the rest of
the brain is one of a degree, not of a kind, and there is a ﬁnding of dif-
ferential effects of age and vascular risk on temporal and parietal
WMH as well [95]. However, the frontal lobes appear most consis-
tently affected.
The reason for such a pattern of selective vulnerability is unclear,
but it may stem from the inherent sensitivity of the regional white
matter to hypoperfusion. A relatively sparse network of perforating
arteries irrigates white matter and age-related changes in vascular
structure, such as capillary loss, tortuosity of arterioles and accumula-
tion of collagen in veins and venules impede cerebral blood ﬂow
(CBF) [86]. Hypertension, with its negative impact on the coronary
ﬂow reserve [87], microvasculature [87] and epithelial function [88]
is accompanied by signiﬁcant reduction in regional CBF [89]. Hyper-
tension is also associated with reduced vasoreactivity, independent
of WMH and stroke, and the relationship is the strongest in the fron-
tal and parietal regions and is driven mainly by elevated systolic
blood pressure [90].
As WMH cluster around watershed regions of the major cerebral
arteries, it is plausible that age-related decline in cerebral blood
ﬂow and chronic hypoperfusion may underpin formation and spread
of the lesions [91]. Indeed, regional CBF [92,93] is reduced within
WMH borders, and persons with signiﬁcant expansion of WMH evi-
dence greater decline in CBF than those whose WMH burden evi-
denced lesser increases [94]. It is worth noting that in the frontal
and parietal regions, anti-hypertensive therapy was the least inﬂuen-
tial in reducing age-related declines in rCBF [89]. Thus, it is plausible
that the observed regional distribution of effects of age, hypertension,
and polymorphisms on WMH reﬂects heightened sensitivity of fron-
tal watershed areas to hypoperfusion and ischemia.
We noted an interesting pattern of relationships between an estab-
lished vascular risk factor, tHcy, age and lobar WMH volumes. Jointly,
older age and higher tHcy levels are associated with larger WMH vol-
umes in frontal, parietal and temporal lobes. In the occipital lobe,
middle-aged individuals with high tHcy levels have the largest WMH.
Elevated tHcy is a risk factor for vascular disease [37,38], longitudinal
expansion of occipital WMH may be associated with elevated vascular
risk [94,95] and accumulation of WMH in the occipital lobe is linked
to poor vascular and psychiatric outcomes [96]. Thus, it is possible
that the participants who exhibited largeWMH volume in the occipital
lobes represent a subgroup that is at risk for cerebral and cognitive de-
clines, a hypothesis that only a longitudinal study can test.
The effect of elevated levels CRP, especially in conjunction with
hypertension may exacerbate endothelial dysfunction in poorly per-
fused watershed areas more than in other, better-irrigated regions.
In addition, IL-1β increases blood–brain barrier permeability [52],
and its elevated expression in the brain of IL-1β-511T homozygotes
may promote formation of WMH in periventricular regions. CRP syn-
thesis is inﬂuenced by multiple proinﬂammatory cytokines, including
IL-1 [97,98] and it would be interesting to test whether genetic pre-
disposition to have both of them elevated is associated with incre-
mental increase in WMH load. In this sample, there were only six
participants who carried CRP T allele and were IL-1β T homozygotes.
Although such a small number precludes including the CRP×IL-1β in-
teraction in the model, comparison of the WMH volumes reveals that
persons who carried this double-risk combination indeed had larger
WMH volumes than the rest of the sample. Thus, a possibility ofepistasis between two pro-inﬂammatory polymorphisms should be
considered in larger samples.
The results of this study should be interpreted in the context of
several limitations. First, this is a cross-sectional study, and therefore
cannot elucidate age-related changes and individual differences
therein. However, multiple longitudinal studies have conﬁrm the pro-
gressive nature of age-related increase in WMH load (see [1] for a re-
view) and it is probably safe to say that the observed age-related
differences represent a snapshot of that process.
Second, the composition of the sample employed in this study im-
poses limits on generalization of the ﬁndings. Although the partici-
pants reported no symptoms and none of them carried a diagnosis,
many of them had signiﬁcant risk factors for developing vascular dis-
ease. Although our goal was to study healthy aging, and we screened
the participants for history of overt disease, it would be virtually im-
possible to ﬁnd a sample of middle-aged and older adults who would
be free of all vascular risk factors, such as hypertension and
hyperlipidemia.
Third, the size of the sample available for this study did not allow in-
vestigation of interactions among the genetic variants. Previous studies
showed that genes that exert no signiﬁcant effects on their ownmay af-
fect WMH load through epistasis. For example, in one study, carriers of
MTHFR 677T or ACE D alleles had increased WMH burden only when
they also carried APOE ε4 or ε2 alleles [99]. In our sample, there was a
possibility of epistasis between two inﬂammation-related SNPs, but in-
sufﬁcient number of participants precluded formal testing of that
possibility.
Fourth, we did not assess actual blood levels of angiotensin II and
interleukin-1β, and thus did not ascertain that in this sample, the ge-
netic randomization indeed resulted in manipulation of blood bio-
markers, as was the case for CRP and LDL but not for tHcy. The fact
that MTHFR 677T allele was not associated with elevated homocyste-
ine levels, may reﬂect uncontrolled manipulation of two signiﬁcant
metabolic actors in the one-carbon cycle: folate and vitamin B12
through diet. Indeed, in this sample, the levels of folate that can be re-
liably manipulated by nutritional means [100] were rather high.
According to the Ofﬁce of Dietary Supplements of the National Insti-
tutes of Health it is quite common for a breakfast cereal, a staple
food for many Americans, to contain 25%–100% of daily allowance of
vitamins B9 (folic acid, a synthetic form of folate), B6, and B12
(http://ods.od.nih.gov/factsheets/folate/, accessed June 14, 2011).
Whether such nutrition manipulation affected the possible link be-
tweenWMH volume andMTHFR 677T allele remains to be investigat-
ed in studies with more precise measures of nutrition. Because we did
not measure blood levels of Il-1β, we cannot conﬁrm that the exam-
ined genetic variant indeed results in elevation of this cytokine's
levels.
Fifth, we examined only one cytokine gene polymorphism among
many that can inﬂuence pro- and anti-inﬂammatory response. There-
fore, additional candidate genes that control expression of cytokines,
such as IL-6, may explain signiﬁcant proportion of variance in WMH
and other brain features.
In summary, genetic variants that are associated with enhanced
pro-inﬂammatory activity increase the volume of WMH. The effects
are independent of well-known risk factors for WMH, such as
age and hypertension. The ﬁnding of association between one of the
hallmarks of brain aging and genetic risk for enhanced inﬂammatory
response is in accord with the theories that view aging and inﬂamma-
tion as inseparable aspects of the same phenomenon [48,101] dubbed
“inﬂammaging” [102]. If this were indeed the case, in longitudinal
studies one would expect to ﬁnd steeper rates of neural and cognitive
decline in persons carrying higher genetic load of pro-inﬂammatory
risk. As anti-hypertensive treatment has only meager success in slow-
ing age-related brain changes [103,104], anti-inﬂammatory interven-
tion for individuals at risk may be an additional rout of intervention in
attempt to stave age-related declines in brain and cognition.
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